

Erratum

LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer: Erratum

Biao Zheng^{1,2*}, Jianhua Qu^{3*}, Kenoki Ohuchida^{2,4}✉, Haimin Feng², Stephen Jun Fei Chong³, Zilong Yan⁵, Yicui Piao⁶, Peng Liu¹, Nan Sheng², Daiki Eguchi², Takao Ohtsuka², Kazuhiro Mizumoto^{2,7}, Zhong Liu¹, Shazib Pervaiz^{3,8,9}, Peng Gong^{1,10}✉ and Masafumi Nakamura²✉

1. Department of General Surgery, Shenzhen University General Hospital / Shenzhen University Clinical Medical Academy, Shenzhen, Guangdong 518055, China.
2. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
3. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore 117593.
4. Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
5. Hepato-pancreato-biliary Surgery Department, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518055, China.
6. Department of Critical Care Medicine, National Cancer Center/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, China.
7. Cancer Center of Kyushu University Hospital, Fukuoka 812-8582, Japan.
8. NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore 117593.
9. National University Cancer Institute, National University Health System, Singapore 119074.
10. Carson International Cancer Research Centre, Shenzhen University School of Medicine, Shenzhen, Guangdong 518055, China.

*These authors contributed equally to this article.

✉ Corresponding authors: Kenoki Ohuchida, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan. E-mail: kenoki@surg1.med.kyushu-u.ac.jp; Peng Gong, Department of General Surgery, Shenzhen University General Hospital/Shenzhen University Clinical Medical Academy, 1098 Xueyuan Road, Shenzhen, Guangdong 518055, China. E-mail: doctorgongpeng@szu.edu.cn; Masafumi Nakamura, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan. E-mail: mnaka@surg1.med.kyushu-u.ac.jp.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <http://ivyspring.com/terms> for full terms and conditions.

Published: 2021.11.10

Corrected article: *Theranostics* 2020; 10(22): 10274-10289. doi: 10.7150/thno.47001.

In the original Figure 6C of our article [1], we mistakenly repeatedly used the LAMA4 shRNA-1 knockdown figure (Figure 6C, bottom middle) as the LAMA4 shRNA-2 knockdown figure (Figure 6C, bottom right) in the cell migration assay of CAFs. The Figure 6C should be corrected as follows. The figure corrected in this erratum does not influence any original conclusions in our study. We apologize for any inconvenience or misunderstanding that this error may have caused.




Figure 6. C. Cell migration assay of CAFs was performed after non-contact co-culture with either WT pancreatic cancer cells or pancreatic cancer cells subjected to LAMA4 knockdown.

References

1. Zheng B, Qu J, Ohuchida K, Feng H, Chong SJF, Yan Z, Piao Y, Liu P, Sheng N, Eguchi D, Ohtsuka T, Mizumoto K, Liu Z, Pervaiz S, Gong P, Nakamura M. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer. *Theranostics* 2020; 10(22):10274-10289. doi:10.7150/thno.47001.